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Introduction: The aim of the present study was to evaluate the effi-
cacy and tolerability of vandetanib plus gemcitabine (V/G) compared 
with gemcitabine alone in elderly patients with untreated advanced 
non–small-cell lung cancer.
Methods: This was a phase II, randomized, double-blind study. A 
total of 124 elderly patients (mean age, 75 yr; age range, 70–84 
yr; 73% men) received V/G (n = 61) or placebo plus gemcitabine 
(n = 63). Progression-free survival (PFS) was the primary endpoint. 
Secondary endpoints were overall survival, objective response rate, 
duration of response, disease control rate, time to deterioration of 
performance status, and safety outcomes.
Results: PFS was significantly prolonged with V/G (median, 183 
days; 95% confidence interval, 116–214) compared with placebo 
plus gemcitabine (median, 169 days; 95% confidence interval, 95–
194; p = 0.047). No statistically significant differences between arms 
were observed in all secondary endpoints, including overall survival. 
The addition of vandetanib to gemcitabine was well tolerated. The 
rate of patients with ≥1 treatment-related adverse event was compa-
rable in the two arms, pyrexia, dyspnea, and neutropenia being the 
most common adverse events.
Conclusions: V/G combination was associated with a statistically 
significant prolongation of PFS compared with gemcitabine alone in 
untreated elderly patients with advanced non–small-cell lung cancer, 
with an acceptable safety profile.
Key Words: Vandetanib, Gemcitabine, Non–small-cell lung cancer, 
Elderly.
(J Thorac Oncol. 2014;9: 733–737)
Vandetanib is a novel small-molecule tyrosine kinase (TK) inhibitor with antiepidermal growth factor recep-
tor, antivascular endothelial growth factor receptor-2, and 
anti-rearranged during transfection TK activity.1 In pretreated 
non–small-cell lung cancer (NSCLC) patients, vandetanib 
monotherapy did not show an overall survival (OS) advantage 
when compared with placebo2 and had a similar progression-
free survival (PFS) when compared with erlotinib.3 Vandetanib 
showed a slight improvement in PFS when administered in 
association with docetaxel versus docetaxel alone4 and a trend 
to improved PFS with the combination vandetanib plus peme-
trexed versus pemetrexed alone.5 However, both trials resulted 
in improved lung cancer symptom control.
Although there is evidence that a platinum-based dou-
blet may be effective,6 single-agent chemotherapy with a 
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third-generation drug (e.g., vinorelbine, gemcitabine, or tax-
ane) was, at the time of the start of study, a recommended 
option for unselected elderly patients with advanced NSCLC.7 
A recently published meta-analysis on benefit-to-risk ratio 
of doublets in advanced NSCLC concluded that combina-
tion platinum-based therapy in NSCLC patients more than 70 
years old may be more favorable than single agents on overall 
response rate (ORR), but not on OS.8
This phase II randomized, double-blind,  placebo-controlled 
study was designed to determine whether the addition of van-
detanib to gemcitabine, in comparison to gemcitabine as single 
agent, significantly prolongs PFS in untreated elderly patients 
with advanced NSCLC.
METHODS
This study included patients aged ≥70 years with 
confirmed stage IIIB/IV NSCLC (according to UICC 
TNM Classification of Malignant Tumours, 6th edi-
tion), anticancer therapy naïve, WHO PS (World Health 
 Organization-performance status) of 0–2, measurable disease 
according to Response Evaluation Criteria in Solid Tumors, 
life expectancy ≥12 weeks, and no significant hematologic, 
hepatic, renal, or cardiac abnormalities. Patients with brain 
metastases were eligible if they had not received treatment 
within the 4 weeks before entry and stable without steroid 
treatment for 10 days. Patients receiving any treatment known 
to have an effect on NSCLC (except palliative radiotherapy 
and bisphosphonates for bone metastases) within 4 weeks 
before the start of study were excluded.
Written informed consent was obtained from each par-
ticipant. The study was approved by the Ethics Committee of 
each site.
Eligible patients were randomized 1:1 to receive van-
detanib plus gemcitabine (V/G) or placebo plus gemcitabine 
(P/G). The computer-generated randomization scheme was 
strictly sequential with blocks of randomization codes being 
sent to each center according to the recruitment potential.
Vandetanib or placebo was administered as single 
oral 100 mg daily doses. Gemcitabine was administered at a 
1200 mg/m2 dose as an intravenous infusion on day 1 and day 
8 of each 21-day cycle (maximum 6). Treatment was discon-
tinued once a patient experienced disease progression or a ≥3 
grade toxicity.
Radiological evaluation using RECIST 1.0 was per-
formed at baseline and every 6 weeks until progression.
Primary endpoint of the study was PFS. Secondary end-
points were OS; ORR (complete response or partial response); 
duration of response; disease control rate (percentage of patients 
with complete response or partial response or stable disease 
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FIGURE 1.  Disposition of patients and reasons for withdrawal. *Patients may have more than one reason for withdrawal. AE, 
adverse event; DP, disease progression.
735Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 5, May 2014 V/G or G/P in NSCLC Elderly Patients
≥6 wk); and time to deterioration of performance status (TDPS, 
the time from randomization to a change from baseline ≥1).
Safety analyses included adverse events (AEs), labora-
tory parameters, vital signs, and electrocardiogram.
Assuming a median PFS of 3 months for gemcitabine,9 
a minimum of 122 patients (61 per arm) were planned to 
detect a 50% prolongation with V/G (median PFS of 4.5 
months), assuming an accrual period of 12 months, a maxi-
mum  follow-up time of 20 months, and no drop-outs. For this 
comparison, 110 progression events were required.
In the PFS analysis, survival curves, medians, and their 
95% confidence intervals (CIs) were estimated applying the 
Kaplan-Meier method. The log-rank test was used to compare 
PFS outcomes. The Cox’s proportional hazard regression model 
was used to analyze covariates of interest (tumor stage, number of 
organs involved, prior adjuvant chemotherapy, histology, smok-
ing history, gender, QTc prolongation, and tumor response).
Time-dependent variables (OS, duration of response, 
and TDPS) were analyzed like PFS. The comparison between 
groups in ORR, disease control rate, and proportion of 
patients alive at 1-year postrandomization was performed by 
chi-square test.
AEs were classified by primary system organ class 
according to the MedDRA thesaurus version 12. For continu-
ous variables, the change from baseline to each postbaseline 
visit was calculated.
RESULTS
This study was conducted from October 2008 to 
December 2011 in 17 sites in Italy. Figure 1 shows the dispo-
sition of patients and reasons for withdrawal. Demographic 
and other baseline characteristics were comparable in the two 
arms (Table 1).
The median number of cycles of gemcitabine infusions 
was 4 (range, 1–6) in both arms, with a similar percentage of 
patients receiving the complete scheme of gemcitabine (40% for 
each arm). The median exposure was 78.5 days (range, 1–528) 
in the V/G arm and 91 days (range, 1–441) in the P/G arm.
Table 2 summarizes efficacy results. Median PFS 
(Figure 2) was significantly prolonged in the V/G arm 
(183 days; 95% CI, 116–214) compared with the P/G arm 
(169 days; 95% CI: 95–194; p = 0.047). In the V/G arm, 
10 patients (16.4%) were censored and 51 failed treat-
ment, whereas five patients (7.9%) were censored and 58 
failed in the P/G arm. The adjusted Cox regression analysis 
on PFS showed that only sex had a statistically significant 
effect (hazard ratio of female patients versus male patients: 
0.63; 95% CI, 0.40–0.99; p = 0.043). The explorative analy-
sis showed that median PFS was significantly prolonged in 
the V/G arm compared with the P/G arm for the following 
covariates: patients with all combined types of histological 
tumors except squamous cell carcinoma (V/G arm: 196 days; 
95% CI, 160–245; P/G arm: 162 days; 95% CI, 87–191; 
p = 0.008); never/past smokers (V/G arm: 188 days; 95% CI, 
129–236; P/G arm: 169 days; 95% CI, 99–194; p = 0.048); 
and female patients (V/G arm: 245 days; 95% CI, 175–693; 
P/G arm: 91.5 days; 95% CI, 45–224; p = 0.010).
In the V/G arm, 37 patients (60.7%) had no World 
Health Organization-performance status increase from base-
line and 24 (39.3%) had ≥1 point increase compared with 31 
patients (49.2%) with no increase and 32 (50.8%) with dete-
rioration in the P/G arm.
The rate of patients with at least one AE was 96.7% and 
98.4% for arm V/G and P/G, respectively. Serious AEs were 
reported in 42.6% in arm V/G and 32.7% in arm P/G.
Ten patients (16.4%) in arm V/G and eight (12.7%) in 
arm P/G died, mostly for disease progression. Dose adjust-
ment, temporary interruption, or permanent discontinuation 
of study drug was required in 72.1% of V/G and 60.3% of 
P/G. Grade IV toxicities were reported in five patients (8.2%) 
in the V/G arm and in five (7.9%) in the P/G arm. Table 3 
shows the most common AEs. Five patients (8.2%) in the V/G 
arm and two (3.2%) in the P/G arm had at least one QTc inter-
val prolongation during the study.
TABLE 1.  Summary of Demographic and Other Baseline 
Characteristics and of Tumor History
Vandetanib/ 
Gemcitabine
Placebo/ 
Gemcitabine
n = 61 n = 63
Sex, n (%)
  Males 45 (73.8) 45 (71.4)
  Females 16 (26.2) 18 (28.6)
Age (yr), mean (range) 75.03 (70–82) 75.48 (70–84)
WHO PS, n (%)
  Grade 0 33 (54.1) 38 (60.3)
  Grade 1 27 (44.3) 24 (38.1)
  Grade 2 1 (1.6) 1 (1.6)
Smoking history, n (%)
  Never smoked 8 (13.1) 13 (20.6)
  Current smokers 15 (24.6) 16 (25.4)
  Past smokers 37 (60.7) 34 (54.0)
  Missing 1 (1.6) —
Previous radiotherapy, n (%) 13 (21.3) 8 (12.7)
Type of tumor, n (%)
  Squamous cell carcinoma 13 (21.3) 17 (27.0)
  Adenocarcinoma 31 (50.8) 41 (65.1)
  Bronchoalveolar carcinoma 3 (4.9) 1 (1.6)
  Large cell carcinoma 2 (3.3) —
  Other or missing 12 (19.6) 4 (6.3)
Grade of histopathological 
diagnosis, n (%)
  Well differentiated (grade 1) 4 (11.4) —
  Moderately differentiated 
(grade 2)
4 (11.4) 4 (12.1)
  Poorly differentiated (grade 3) 8 (22.9) 11 (33.3)
  Unknown or missing 19 (54.3) 18 (54.6)
Stage at study entry, n (%)
  IIIB (supraclavicular lymph 
node metastases)
6 (9.8) 7 (11.1)
  IV 55 (90.2) 56 (88.9)
WHO PS, World Health Organization performance status.
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DISCUSSION
This study compared the efficacy and tolerability of 
treatment with vandetanib given in addition to gemcitabine 
versus gemcitabine plus placebo in 124 untreated elderly 
patients with advanced NSCLC and satisfactory health status 
and organ function.
The two treatment groups were balanced in terms of 
demographic and baseline characteristics, including tumor 
staging and prognostic factors. Results of the primary end-
point showed that PFS was significantly prolonged in the V/G 
arm compared with P/G. The significant benefit in the V/G 
group was obtained despite the PFS in the control group was 
longer than expected.9 However, our assumption of a 50% PFS 
prolongation was not reached.
The preplanned subgroups’ explorative analysis showed 
that PFS was significantly prolonged with V/G compared with 
P/G alone in patients with all types of histological tumors 
except squamous cell carcinoma, in never/past smokers and 
in female patients. However, it should be noted that the sub-
populations, in which a statistically significant difference 
between arms was not observed, included a limited number of 
patients, which were likely not adequately powered for a reli-
able comparison between arms. Of all secondary endpoints, 
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FIGURE 2.  Progression-free survival: Kaplan-Meier estimate 
of survival distribution function—unadjusted.
TABLE 3.  Most Common AEs of Any Grade (i.e., Reported 
in ≥10% of Patients in Either Arm) and of Grade ≥3 (i.e., 
Reported in ≥2% of Patients in Either Arm)
Vandetanib/ 
Gemcitabine
Placebo/ 
Gemcitabine
n = 61 n = 63
AEs of any grade
  Pyrexia 17 (27.9) 17 (27.0)
  Dyspnea 13 (21.3) 19 (30.2)
  Neutropenia 17 (27.9) 14 (22.2)
  Fatigue 14 (23.0) 15 (23.8)
  Thrombocytopenia 14 (23.0) 13 (20.6)
  Anorexia 8 (13.1) 17 (27.0)
  Asthenia 9 (14.8) 13 (20.6)
  Rash 15 (24.6) 5 (7.9)
  Anemia 8 (13.1) 14 (22.2)
  Diarrhea 9 (14.8) 9 (14.3)
  Cough 9 (14.8) 10 (15.9)
  Nausea 7 (11.5) 8 (12.7)
  Edema peripheral 4 (6.6) 12 (19.0)
  Chest pain 2 (3.3) 12 (23.8)
  Vomiting 4 (6.6) 7 (11.1)
  Hypokalemia 3 (4.9) 8 (12.7)
Grade ≥3 AEsa
  Neutropenia 7 (11.5) 8 (12.7)
  Dyspnea 5 (8.2) 7 (11.1)
  Fatigue 4 (6.6) 3 (4.8)
  Anemia 3 (4.9) 2 (3.2)
  Thrombocytopenia 4 (6.6) 2 (3.2)
  Pulmonary embolism 3 (4.9) 3 (4.8)
  Pneumonia 2 (3.3) —
  Pulmonary edema 3 (4.9) —
  Respiratory failure 1 (1.6) 2 (3.2)
  Asthenia — 2 (3.2)
  Rash 2 (3.3) —
  Cerebral ischemia — 2 (3.2)
Data are number (%) of patients.
aAccording to the NCI CTCAE, Version 3.0.
AE, adverse event.
TABLE 2.  Summary of Results of Efficacy
Vandetanib/Gemcitabine Placebo/Gemcitabine
pan = 61 n = 63
PFS (days), median (95% CI) 183 (116–214) 169 (95–194) 0.047
OS (days), median (95% CI) 262 (170–245) 305 (213–355) 0.896
Alive at one year, n (%) 19 (31.1) 19 (30.2) 0.90
Objective response, n (%) 9 (14.8) 8 (12.7) 0.74
DOR (days), median (95% CI) 225 (175–0) 214 (124–232) 0.162
Disease control, n (%) 44 (72.1) 42 (66.7) 0.51
TDPS (days), median (95% CI) 167 (64–0) 111 (79–188) 0.659
aLog-tank test in survival function data and chi-square test in proportions.
PFS, progression-free survival; CI, confidence interval; OS, overall survival; DOR, duration of response; TDPS, time to deterioration of performance status.
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no statistically significant differences were found, including 
tumor response and survival.
The addition of vandetanib to gemcitabine was associ-
ated with a satisfactory toxicity profile. Pyrexia, dyspnea, and 
neutropenia were the most common AEs and were observed 
in comparable rates in the two arms, being neutropenia and 
pyrexia the results of gemcitabine-induced myelosuppression 
and dyspnea a disease-related symptom.
Among the other most common AEs related to vande-
tanib, the incidence of diarrhea was comparable in the two treat-
ment arms, whereas skin rash was more frequent in patients in 
the V/G arm than in the P/G arm. In the present study, vande-
tanib may have caused rash in a lower proportion of patients 
than that previously reported.10 Among the cardiovascular 
side effects, less than 10% of patients treated with vandetanib 
reported increased blood pressure, with no cases of grade III–IV 
hypertension in either arm, and none of the patients with blood 
pressure elevation required treatment discontinuation, interrup-
tion, or delay due to this event. QT interval prolongation has 
also been reported in clinical trials with vandetanib,11 particu-
larly in view of the long terminal elimination half-life of the 
drug.12 In this study, a QTc interval prolongation was reported 
in five patients treated with vandetanib and in two in the control 
group. However, this event was not associated with an increase 
in risk of serious cardiac events in the V/G arm.
To our knowledge, this is the first study conducted in 
elderly patients with vandetanib and the first evidence of its 
combination with gemcitabine. Consistent with previous tri-
als,13 an improvement in PFS in the vandetanib arm did not 
translate into an improvement in OS. However, the group of 
patients who received vandetanib in this and in previous trials 
experienced a delay in TDPS, suggesting palliative benefits.
Taking into account the results of this phase II study in 
terms of efficacy and safety, further research is of interest to 
better identify the group of patients who might benefit from 
vandetanib treatment.
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